Please ensure Javascript is enabled for purposes of website accessibility

Why Amyris Stock Jumped Today

By Keith Speights – Aug 20, 2021 at 3:51PM

Key Points

  • Amyris reported encouraging results from an in vivo study of an intranasal COVID-19 vaccine that it's developing with the Infectious Disease Research Institute.
  • The company didn't provide many details from the results but plans to do so at an upcoming webinar.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced promising results from a study of its experimental intranasal COVID-19 vaccine.

What happened

Shares of Amyris (AMRS -1.11%) were jumping 14.8% as of 3:43 p.m. EDT on Friday. The big gain came after the synthetic biology company announced encouraging in vivo (in the body) results from a study evaluating an intranasal RNA COVID-19 vaccine Amyris is developing with the Infectious Disease Research Institute.

So what

Amyris said the results from the study found that its intranasal vaccine generates antibodies against SARS-CoV-2 and provides protection from upper respiratory infection by the virus. The company thinks the experimental vaccine could provide more protection against coronavirus variants than current messenger RNA vaccines do.

Gloved hand holding a COVID-19 intranasal vaccine container.

Image source: Getty Images.

It's been a good year for Amyris so far, with the biotech stock nearly doubling year to date as of the market close on Thursday. Today's news generated even more enthusiasm among investors.

However, Amyris still has multiple hurdles to jump before it could potentially market its COVID-19 vaccine. And the company, along with IDRI, would likely target developing nations that won't be able to pay as much as countries such as the U.S. even if the vaccine wins regulatory approvals.

Now what

Amyris didn't provide a lot of information from its latest results. The company said it plans to give a more detailed update during an upcoming investor webinar.  

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Amyris Stock Quote
Amyris
AMRS
$1.78 (-1.11%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.